Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the target of unusually large options trading on Wednesday. Investors purchased 1,074 call options on the stock. This represents an increase of approximately 1,031% compared to the typical daily volume of 95 call options.

Several institutional investors have recently modified their holdings of AERI. Ameritas Investment Partners Inc. raised its stake in shares of Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after purchasing an additional 275 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Aerie Pharmaceuticals by 792.5% in the third quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after purchasing an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Aerie Pharmaceuticals by 2,711.4% in the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after purchasing an additional 3,579 shares during the last quarter. Amalgamated Bank purchased a new stake in shares of Aerie Pharmaceuticals in the second quarter worth approximately $204,000. Finally, Great West Life Assurance Co. Can raised its stake in shares of Aerie Pharmaceuticals by 65.0% in the third quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after purchasing an additional 1,639 shares during the last quarter.

Several research analysts have issued reports on AERI shares. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Mizuho reiterated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a report on Wednesday, September 20th. Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, September 22nd. Cowen reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. Finally, Zacks Investment Research lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $72.00.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at $59.35 on Friday. The company has a market capitalization of $2,180.00, a P/E ratio of -17.72 and a beta of 1.11. Aerie Pharmaceuticals has a 52 week low of $37.80 and a 52 week high of $66.60. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/06/stock-traders-purchase-high-volume-of-aerie-pharmaceuticals-call-options-aeri.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.